CRISPR Therapeutics to Join June 2024 Investor Conferences

ZUG, Switzerland and BOSTON, May 29, 2024-- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical pioneer in gene-based medicine for serious diseases, disclosed that its senior management team will participate in two upcoming investor conferences in June 2024.

The first event in their schedule is the Jefferies Healthcare Conference, set for Wednesday, June 5, 2024, at 10:00 a.m. Eastern Time (ET). The second is Goldman Sachs' 45th Annual Global Healthcare Conference, which will take place on Tuesday, June 11, 2024, at 9:20 a.m. ET.

For those interested in following these events, a live webcast of the presentations will be accessible via the "Events & Presentations" page located in the Investors section of CRISPR Therapeutics' website. Additionally, the webcasts' replays will be available on the same platform for a duration of 14 days after the live presentations.

About CRISPR Therapeutics

Founded over a decade ago, CRISPR Therapeutics has evolved from a company in its research phase to one that celebrates a historic milestone: the approval of the first-ever CRISPR-based therapy. The company now boasts a broad portfolio of product candidates addressing various disease areas, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases.

In 2018, CRISPR Therapeutics introduced the first CRISPR/Cas9 gene-edited therapy to clinical trials, targeting the treatment of sickle cell disease and transfusion-dependent beta thalassemia. By late 2023, their product CASGEVY™ (exagamglogene autotemcel) received approval in certain countries for treating eligible patients with these conditions.

The innovative CRISPR technology has significantly advanced biomedical research, offering a powerful and clinically validated approach to developing transformative medicines. The company has forged strategic partnerships with industry leaders such as Bayer and Vertex Pharmaceuticals to further accelerate and broaden its research and development efforts.

Headquartered in Zug, Switzerland, CRISPR Therapeutics operates its U.S. subsidiary, CRISPR Therapeutics, Inc., with R&D facilities in Boston, Massachusetts, and San Francisco, California. They also maintain business offices in London, United Kingdom.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!